Building A New Model For Developing New Therapies: An Interview With AstraZeneca's Strategic Alliance Asia Director Richard Wang
This article was originally published in PharmAsia News
Executive Summary
Although AstraZeneca is paring down its pipeline by halting discovery efforts in 10 specific diseases, which account for 25 percent of the total diseases that earlier drove research by AstraZeneca ("The Pink Sheet" Daily, March 2, 2010), it won't stop R&D expansion plans in China. As big pharmaceutical firms compete to find the next generation of innovative drugs, translational science may help companies to find the right drug for the right patient and bring these medicines to market faster. During the recent Asia Pharma R&D Leaders conference in Shanghai, Richard Wang, AstraZeneca's Director of Strategic Alliances - Asia, sat down with PharmAsia News' Shanghai Bureau to discuss the strategy of AstraZeneca's Innovation Center China and how translational science is helping the company develop new compounds.
You may also be interested in...
Qiagen Forms JV With Shanghai's Bio-X Center For Translational Research In China
Qiagen forms JV with Shanghai Jiao Tong University for translational research to focus on biomarkers, diagnostics for developing drugs specifically for Asians.
MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how
To succeed in China's fast-growing oncology market, multinational pharma companies need to look closely at their product mix and figure out whether getting listed on the country's reimbursed drug list will increase volume enough to offset price reductions, or whether it makes more sense to charge full retail prices to patients paying out-of-pocket and settle for lower volume
MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how
To succeed in China's fast-growing oncology market, multinational pharma companies need to look closely at their product mix and figure out whether getting listed on the country's reimbursed drug list will increase volume enough to offset price reductions, or whether it makes more sense to charge full retail prices to patients paying out-of-pocket and settle for lower volume